Last updated: September 23, 2026
Neumega, the brand name for oprelvekin, was a recombinant interleukin-11 therapy developed by Genetics Institute and commercialized by Wyeth for reducing chemotherapy-induced severe thrombocytopenia. The FDA approved it in 1997, but safety concerns, limited clinical utility, manufacturing issues, and competition from platelet transfusions and newer thrombopoietic agents weakened its commercial position. Neumega was later withdrawn from the U.S. market for business reasons, and it no longer has a meaningful U.S. revenue base.
No reliable public source reports standalone annual Neumega sales. Its financial trajectory is therefore best assessed through approval history, market access, competitive displacement, product withdrawal, and the absence of current commercial activity rather than through a verified revenue series.
What was Neumega and how did oprelvekin work?
Neumega contained oprelvekin, a recombinant form of human interleukin-11. The drug stimulated megakaryocyte development and platelet production in the bone marrow.
The FDA approved Neumega on Nov. 12, 1997, for reducing the need for platelet transfusions in adult patients receiving myelosuppressive chemotherapy for nonmyeloid malignancies who had experienced severe thrombocytopenia in a prior chemotherapy cycle [1].
Its label did not position Neumega as a general treatment for all chemotherapy-related thrombocytopenia. The approved use was narrower and depended on a prior episode of severe thrombocytopenia. That limitation reduced the eligible population and restricted routine prophylactic use.
What was Neumega’s approved dosage form?
Neumega was supplied as a lyophilized powder for subcutaneous injection. The recommended adult dose was 50 micrograms per kilogram once daily, generally initiated after chemotherapy and administered for a defined treatment period under the product label [1].
The product required reconstitution and injection. This created handling and administration costs relative to oral thrombopoietic agents that later entered adjacent markets.
When did Neumega lose exclusivity and commercial momentum?
Neumega’s commercial decline began before the product’s full market withdrawal. Several factors reduced demand:
| Factor |
Effect on Neumega |
| Narrow FDA indication |
Limited eligible chemotherapy population |
| Cardiovascular and fluid-retention risks |
Reduced physician willingness to use the drug |
| Need for subcutaneous administration |
Added treatment burden |
| Platelet transfusions |
Remained an established rescue and prophylactic option |
| Chemotherapy changes |
Lowered the incidence of severe thrombocytopenia in some regimens |
| Competing growth factors and supportive-care strategies |
Reduced reliance on IL-11 therapy |
| Absence of a broad oncology-supportive-care market |
Constrained volume growth |
Neumega did not develop the durable blockbuster profile achieved by several colony-stimulating factors or later thrombopoietin-receptor agonists. Its clinical value was concentrated in a narrow use case, while its adverse-event profile affected adoption.
The original biologic and manufacturing patent estate was commercially relevant during the launch and early post-launch period. Patent expiry dates are not the primary reason for the product’s current absence from the market. The more important event was commercial withdrawal and loss of active U.S. market support.
What is the FDA regulatory status of Neumega?
Neumega is not an active U.S. growth product. Wyeth discontinued the product in the United States, and Pfizer later became the relevant successor company following its acquisition of Wyeth in 2009.
The FDA’s Drugs@FDA materials and product labeling establish the product’s approval history and safety profile. Neumega’s withdrawal was associated with commercial considerations rather than a formal FDA finding that the drug was unsafe or ineffective for every labeled use.
What safety issues affected Neumega demand?
The prescribing information identified serious risks associated with fluid retention and cardiovascular effects. Reported adverse reactions included:
- Peripheral edema
- Dyspnea
- Tachycardia
- Arrhythmias
- Atrial fibrillation or flutter
- Pulmonary edema
- Capillary leak-type effects
- Headache and injection-site reactions
Patients with pre-existing cardiovascular disease were a particular concern. The drug also had a boxed warning related to serious cardiovascular events in certain patients and required careful patient selection and monitoring [1].
The safety profile made Neumega less attractive for prophylactic use when clinicians could instead use platelet transfusions or accept a short period of thrombocytopenia.
How large was the Neumega market?
Neumega’s addressable market was materially smaller than the overall chemotherapy-induced thrombocytopenia population.
The product was not approved to prevent thrombocytopenia in every patient receiving chemotherapy. The label focused on patients with a previous chemotherapy cycle associated with severe thrombocytopenia and platelet-transfusion need. That restriction limited use to a high-risk subset.
No verified public dataset provides a complete annual global revenue history for Neumega. Wyeth and Pfizer reported results at broader company or business-segment levels rather than disclosing a durable, standalone Neumega revenue line. The available public record does not support a precise year-by-year sales estimate without relying on unverified secondary-market projections.
What was Neumega’s financial trajectory?
Neumega followed a lifecycle characterized by early regulatory value, limited commercial expansion, declining clinical adoption, and eventual withdrawal.
| Period |
Commercial development |
| 1997 |
FDA approval for chemotherapy-induced severe thrombocytopenia |
| Late 1990s |
Initial commercialization by Wyeth and use in oncology supportive care |
| Early 2000s |
Safety concerns and limited indication constrained uptake |
| Mid-to-late 2000s |
Product demand weakened as supportive-care practices evolved |
| 2009 |
Pfizer acquired Wyeth and inherited the product portfolio |
| Later period |
U.S. commercial availability ended; no meaningful current U.S. revenue base |
The product’s financial value was also affected by its position in hospital oncology budgets. A therapy that reduces platelet transfusions must demonstrate a clear economic advantage after accounting for drug acquisition, administration, monitoring, adverse-event management, and hospitalization risk. Neumega’s safety profile weakened that economic case.
Which companies challenged Neumega’s market?
Neumega’s principal competitive pressure did not come from a conventional generic or biosimilar launch. It came from alternative treatment strategies.
Platelet transfusions
Platelet transfusion remained the standard intervention for clinically significant thrombocytopenia and active bleeding. Hospitals could use transfusions selectively rather than expose broad patient populations to Neumega’s cardiovascular and fluid-retention risks.
Romiplostim and eltrombopag
Romiplostim and eltrombopag later established themselves as important thrombopoietic agents, particularly in immune thrombocytopenia and selected other settings. Their approved indications were not identical to Neumega’s, but they contributed to the broader clinical shift toward targeted platelet-production therapies.
Chemotherapy regimen changes
Changes in chemotherapy intensity, dose management, cancer treatment protocols, and supportive-care standards also reduced the need for a product designed around predictable chemotherapy-induced thrombocytopenia.
Other supportive-care products
Granulocyte colony-stimulating factors addressed neutropenia rather than thrombocytopenia, but they competed for oncology supportive-care budgets and physician attention. Neumega did not benefit from the same broad, recurring use pattern.
What patents protected Neumega?
Neumega was supported by biotechnology patents covering recombinant interleukin-11, production methods, protein compositions, and pharmaceutical applications. The original rights were associated with Genetics Institute and later transferred or controlled through Wyeth and Pfizer corporate transactions.
The commercial patent questions were less important than the regulatory and clinical limitations:
- Neumega was a biologic, so a conventional small-molecule generic substitution pathway was not available.
- A biosimilar competitor would have required a separate FDA biologics pathway.
- The product’s narrow indication and safety profile reduced the commercial incentive to develop a follow-on product.
- The withdrawal of U.S. commercialization removed much of the economic value of enforcing a remaining patent estate.
Were there Neumega Paragraph IV challenges?
There is no well-established public record of a major U.S. Paragraph IV litigation campaign against Neumega comparable to those involving major small-molecule oncology drugs. That result is consistent with the product’s biologic status, declining market, and limited commercial opportunity.
Paragraph IV certification applies primarily to abbreviated new drug applications for small-molecule products listed in the FDA Orange Book. A biologic such as Neumega would ordinarily be challenged through the applicable biologics framework rather than a conventional ANDA Paragraph IV strategy.
What was Neumega’s Orange Book status?
Neumega’s regulatory history predates the modern commercial biosimilar environment. Orange Book listing is not the central exclusivity mechanism for a recombinant biologic product.
The FDA approval and labeling record is more relevant than Orange Book patent listings for evaluating Neumega’s market position. A product’s withdrawal from commercial distribution also reduces the practical value of any remaining listing, patent, or regulatory exclusivity.
Neumega did not become a significant reference product for a later biosimilar market. No major U.S. biosimilar franchise has emerged around oprelvekin.
Is there biosimilar risk for Neumega?
Current biosimilar risk is low in commercial terms. Oprelvekin is a recombinant biologic, so a follow-on developer would face:
- Limited remaining demand
- Clinical development and comparability costs
- Manufacturing and quality-control requirements
- A small or uncertain reimbursement opportunity
- Competition from transfusion practice and other platelet-support strategies
- The need to establish a viable supply chain for a discontinued or commercially inactive product
A biosimilar could theoretically be developed if an unmet need or regional market emerged. The U.S. economic incentive is weak because Neumega does not have a large active market.
What manufacturing and intellectual-property barriers affect Neumega?
Oprelvekin manufacturing requires recombinant protein expression, purification, formulation, sterile filling, and quality testing. The technical barrier is lower than for a complex monoclonal antibody but still material for a product with limited volume.
Key barriers include:
- Establishing a validated recombinant production process
- Demonstrating consistent protein identity and activity
- Controlling impurities and aggregation
- Matching the reference product’s formulation and delivery characteristics
- Maintaining regulatory-grade supply for a small patient population
- Justifying development costs against likely sales
For Neumega, manufacturing economics are more restrictive than patent exclusivity. A low-volume biologic may have high per-unit production and distribution costs, weakening the case for re-entry.
What litigation affected Neumega?
Neumega has not generated a major recent patent-litigation profile comparable to high-revenue oncology biologics. The public commercial record is dominated by regulatory labeling, safety concerns, product discontinuation, and portfolio ownership changes rather than active infringement disputes.
No major current generic-launch litigation scenario is evident. The absence of an active U.S. commercial market makes new litigation less likely unless a company seeks to revive the product or develop a follow-on biologic.
Did licensing deals influence Neumega’s development?
Genetics Institute developed the interleukin-11 program, while Wyeth commercialized Neumega. Wyeth’s subsequent acquisition by Pfizer changed corporate ownership of the product portfolio.
The key strategic transaction was Pfizer’s acquisition of Wyeth in 2009, not a later licensing deal that created a new Neumega growth platform. After the acquisition, Neumega remained a legacy product rather than a priority growth asset.
How does Neumega compare with current thrombocytopenia treatments?
| Product or strategy |
Mechanism or approach |
Principal market position |
Neumega comparison |
| Oprelvekin |
Recombinant interleukin-11 |
Historical chemotherapy-induced thrombocytopenia use |
Narrow indication and significant safety concerns |
| Platelet transfusion |
Direct replacement of circulating platelets |
Established hospital intervention |
More flexible for urgent treatment |
| Romiplostim |
Thrombopoietin-receptor agonist |
Primarily immune thrombocytopenia and selected uses |
Different approved indications and dosing model |
| Eltrombopag |
Oral thrombopoietin-receptor agonist |
Immune thrombocytopenia and other hematologic settings |
Oral administration and different safety profile |
| Avatrombopag |
Oral thrombopoietin-receptor agonist |
Selected thrombocytopenia indications |
Newer targeted alternative in defined populations |
| Chemotherapy modification |
Dose delay or reduction |
Used when clinically appropriate |
Avoids exposure to an additional platelet-stimulating drug |
Neumega’s commercial weakness came from the combination of a narrow indication, injectable administration, and safety concerns. Newer agents do not need to replace Neumega directly to displace its economic role. They only need to provide a more acceptable option in overlapping or adjacent populations.
What generic entry risks exist for Neumega?
The risk of a conventional generic launch is low because Neumega is a biologic rather than a standard small-molecule product. The more relevant risks would be:
- A follow-on biologic or biosimilar application.
- Reintroduction by a specialty pharmaceutical company.
- Regional commercialization outside the United States.
- Substitution by newer thrombopoietin-receptor agonists.
- Hospital protocol changes that remove the product from supportive-care pathways.
The fifth risk is the most relevant to historical market erosion. Clinical protocols can eliminate demand even when no direct substitute has the same label.
What is the current investment and revenue outlook for Neumega?
Neumega has no credible current U.S. growth thesis. Its investment profile is defined by:
- No established standalone revenue stream
- No active blockbuster-scale market
- Low probability of a major biosimilar market
- Limited value from legacy patents
- High regulatory and manufacturing costs relative to potential demand
- Competition from transfusions and newer thrombopoietic agents
The product may retain historical value for patent analysis, oncology-supportive-care research, and biologic lifecycle studies. It does not represent a meaningful current commercial asset unless a company develops a new indication, a lower-risk formulation, or a targeted regional supply strategy.
Key Takeaways
- Neumega is the brand name for oprelvekin, a recombinant interleukin-11 biologic.
- The FDA approved it in 1997 for reducing platelet-transfusion needs in a defined high-risk chemotherapy population.
- Standalone Neumega revenue was not consistently disclosed by Wyeth or Pfizer.
- Commercial demand was constrained by the narrow label, injectable administration, cardiovascular risks, and fluid retention.
- Platelet transfusions and newer thrombopoietin-receptor agonists reduced the product’s strategic value.
- Neumega was withdrawn from the U.S. commercial market and has no meaningful current U.S. revenue base.
- Conventional Paragraph IV litigation and large-scale biosimilar competition were not major features of its lifecycle.
- Manufacturing economics and weak demand are more important than remaining patent rights.
- The product has limited current investment value absent a new development or commercialization strategy.
FAQs About Neumega Market and Financial History
Is Neumega still available in the United States?
Neumega is not an active U.S. commercial growth product. The product was withdrawn from the U.S. market, and no significant current U.S. revenue base is evident.
Did Pfizer acquire Neumega?
Yes. Pfizer acquired Wyeth in 2009 and inherited Neumega as part of Wyeth’s product portfolio.
Was Neumega a blockbuster drug?
No. Neumega did not achieve the broad sales scale associated with major oncology biologics. Its indication and safety profile limited adoption.
Can a company launch a generic version of Neumega?
A conventional generic is not the normal pathway for a recombinant biologic. A follow-on developer would generally need to pursue the applicable biologics approval route, subject to current FDA requirements.
Why did Neumega fail commercially?
The main factors were its restricted patient population, clinically important cardiovascular and fluid-retention risks, administration burden, competition from platelet transfusions, and the emergence of alternative thrombopoietic treatments.
References
-
U.S. Food and Drug Administration. (1997). Neumega (oprelvekin) prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
-
U.S. Food and Drug Administration. (2018). Biologics license applications and abbreviated approval pathways. FDA.
-
Pfizer Inc. (2009). Pfizer completes acquisition of Wyeth. Pfizer investor and corporate materials.
-
National Cancer Institute. (n.d.). Oprelvekin. NCI Drug Dictionary.
